After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
An in vivo Car-T produced a 100% response rate – in three patients.
Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.
Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.
Arcellx and AstraZeneca take centre stage.
Five years after settling, GSK is again accused of breaching the Jemperli deal.
The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
